- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03405376
Prospective Trial of Treat and Extend Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion
Prospective Trial of Treat and Extend Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion: the PLATON Trial
Study Overview
Status
Intervention / Treatment
Detailed Description
Retinal vein occlusion (RVO) includes central RVO (CRVO) and branch RVO (BRVO). A highly prevalent retinal vascular disease, RVO is second only to diabetic retinopathy. In CRVO, hemorrhages and edema develop throughout the retina, whereas in BRVO the pathology is more sectoral, involving the portions of the retina drained by the obstructed branch vein. This suggests that increased intraluminal pressure behind the obstruction may lead to transudation of blood cells and plasma into the retina. However, recent studies have demonstrated that although increased venous pressure may be the precipitating event for hemorrhages and edema, increased production of vascular endothelial growth factor (VEGF) occurs early in RVO and is a major contributor to their evolution and persistence. In addition, the high levels of VEGF contribute to progression of retinal nonperfusion and hence retinal ischemia, which may in turn increase production of VEGF, and may explain why some eyes enter a vicious cycle of worsening disease often referred to as conversion to an ischemic RVO.
Treat-and-extend intravitreal anti-VEGF with age related macular degeneration and diabetic macular edema has been reported to offer the opportunity to individual management while minimizing treatment burden and similar visual and anatomical outcomes to those with fixed montly dosing.
Also, small retrospective treat-and-extend intravitreal bevacizumab injection for treatment of BRVO associated macular edema demonstrated similar visual outcomes and number of intravitreal injections as did pro-re-nata treatment with ranibizumab conducted in phase 3 trials but with fewer visits and lower annual medical costs.
The effects of afilbercept have been reported to persist for over 8 weeks in DME and AMD studies. In addition, VIBRANT study also demonstrated that bi-monthly injection of aflibercept showed significant visual improvement in BRVO patients.
In the treat-and-extend studies of RVO, ranibizumab has been extended for up to 4 months at intervals of 2 weeks. But, to our knowledge, there was no prospective study of treat-and-extend regiments with intravitreal aflibercept in treatment naïve patients in BRVO.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Jinhee Kim
- Phone Number: 82-53-620-3879
- Email: ey001@ymc.yu.ac.kr
Study Locations
-
-
-
Busan, Korea, Republic of
- Recruiting
- Dong-A University Hospital
-
Contact:
- Woo Jin Jung, MD
-
Busan, Korea, Republic of
- Recruiting
- Maryknoll Medical Center
-
Contact:
- Jung Min Park, MD
-
Daejeon, Korea, Republic of
- Recruiting
- Chungnam National University Hospital
-
Contact:
- Jung Yeul Kim, MD
-
Gwangju, Korea, Republic of
- Recruiting
- Chonnam National University Hospital
-
Contact:
- Yong-Sok Ji, MD
-
-
Deagu
-
Daegu, Deagu, Korea, Republic of, 42415
- Recruiting
- Min Sagong
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Center-involved macular edema secondary to BRVO for no longer than 3 months (at the screening visit it should be ensured that the subjects will comply with the criterion of ≤ 3 months since onset of macular edema at their scheduled baseline visit).
- Adult subjects diagnosed with macular edema secondary to BRVO who are scheduled to be treated with intravitreal aflibercept as per investigator's routine treatment practice with the intent to use a T&E regimen after initial treatment.
- Treatment-naïve subjects for macular edema secondary to BRVO.
- Both ischemic and non-ischemic BRVO, which are confirmed by FA at baselin, week 24 and week 72.
- Men and women ≥ 18 years of age.
- Documented BCVA of ETDRS letter score of 73 to 24 letters (Snellen equivalent of 20/40 to 20/320) in the study eye.
Exclusion Criteria:
- Previous PRP or macular laser photocoagulation in the study eye.
- Any prior or concomitant ocular treatment (e.g. anti-VEGF therapy, corticosteroids) in the study eye for macular edema secondary to BRVO, except dietary supplements or vitamins prior to inclusion in the study. Intraocular anti-VEGF treatment is permitted for the treatment of diseases of fellow eye except for those that are specifically excluded.
- Prior systemic anti-VEGF or corticosteroid therapy, investigational or approved, within the last 3 months before the first dose in the study.
- Previous use of intraocular corticosteroids in the study eye at any time or use of periocular corticosteroids in the study eye within 12 months prior to Day 1.
- Any active intraocular, extraocular, and periocular inflammation or infection in either eye within 4 weeks of screening.
- Any history of allergy to povidone iodine.
- Known serious allergy to the fluorescein sodium for injection in angiography.
- Presence of any contraindications indicated in the EU commission/locally approved label for intravitreal aflibercept: hypersensitivity to the active substance intravitreal aflibercept or to any of the excipients; active or suspected ocular or periocular infection; active severe intraocular inflammation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Branch retinal vein occlusion
Aflibercept 2mg is injected into the vitreous cavity.
Center-involved macular edema secondary to branch retinal vein occlusion for no longer than 3 months (at the screening visit it should be ensured that the subjects will comply with the criterion of ≤ 3 months since onset of macular edema at their scheduled baseline visit)
|
Aflibercept 2mg is injected into the vitreous cavity through the pars plana using 30G needle-attached syringe for branch retinal vein occlusion.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean change of best corrected visual acuity
Time Frame: From baseline to Week 72
|
The mean change of best corrected visual acuity from baseline to Week 72 in early treatment diabetic retinopathy letter score
|
From baseline to Week 72
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean change of best corrected visual acuity
Time Frame: From baseline to Week 24, 52
|
The change in mean best corrected visual acuity at baseline as measured by the early treatment diabetic retinopathy letter score
|
From baseline to Week 24, 52
|
mean change in central macular thickness
Time Frame: From baseline to Weeks 24, 52, and 72
|
The mean change in central macular thickness
|
From baseline to Weeks 24, 52, and 72
|
mean treatment interval between injections
Time Frame: From baseline to Week 72
|
The mean treatment interval between injections
|
From baseline to Week 72
|
gain ≥ 15 letters in best corrected visual acuity
Time Frame: Compared with baseline at Week 24, 52 and 72
|
The proportion of subjects who gain ≥ 15 letters in best corrected visual acuity on the early treatment diabetic retinopathy chart
|
Compared with baseline at Week 24, 52 and 72
|
mean treatment interval between injections of ≥ 12 or 16 weeks
Time Frame: From the last actual visit of the initiation phase to Week 72
|
The proportion of subjects with a mean treatment interval between injections of ≥ 12 or 16 weeks
|
From the last actual visit of the initiation phase to Week 72
|
who reach 16 weeks treatment interval at any time point
Time Frame: up to 72 weeks
|
The proportion of subjects who reach 16 weeks treatment interval at any time point
|
up to 72 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Min Sagong, MD, Yeungnam University Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Eye Diseases
- Retinal Degeneration
- Retinal Diseases
- Embolism and Thrombosis
- Venous Thrombosis
- Thrombosis
- Macular Degeneration
- Macular Edema
- Retinal Vein Occlusion
- Edema
- Physiological Effects of Drugs
- Antineoplastic Agents
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Aflibercept
Other Study ID Numbers
- YUMC2017-07-056-003
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Branch Retinal Vein Occlusion With Macular Edema
-
Taiwan Liposome CompanyCompletedCentral Retinal Vein Occlusion With Macular Edema | Branch Retinal Vein Occlusion With Macular EdemaTaiwan
-
Retina Clinic, Sao Paulo, BrazilFederal University of São PauloCompletedDiabetic Macular Edema | Age Related Macular Degeneration | Central Retinal Vein Occlusion With Macular Edema | Branch Retinal Vein Occlusion With Macular EdemaBrazil
-
St. Erik Eye HospitalUnknownBranch Retinal Vein Occlusion With Macular EdemaSweden
-
Yeungnam University College of MedicineUnknownBranch Retinal Vein Occlusion With Macular EdemaKorea, Republic of
-
Justis EhlersRegeneron PharmaceuticalsCompletedCentral Retinal Vein Occlusion | Diabetic Macular Edema | Retinal Vein Occlusion | Branch Retinal Vein OcclusionUnited States
-
Hanscom, Thomas, M.D.Genentech, Inc.CompletedCentral Retinal Vein Occlusion | Macular Edema | Branch Retinal Vein OcclusionUnited States
-
Tokyo Medical UniversityUnknownCentral Retinal Vein Occlusion | Macular Edema | Branch Retinal Vein OcclusionJapan
-
Santen Pharmaceutical Co., Ltd.CompletedMacular Edema Following Branch Retinal Vein OcclusionJapan, Korea, Republic of
-
Sanwa Kagaku Kenkyusho Co., Ltd.CompletedMacular Degeneration | Macular Edema | Branch Retinal Vein OcclusionJapan
-
Chengdu Kanghong Biotech Co., Ltd.CompletedMacular Edema | Branch Retinal Vein OcclusionChina
Clinical Trials on Intravitreal aflibercept injection
-
Indonesia UniversityBayerCompletedDiabetic Retinopathy | Diabetic Macular Edema | Clinically Significant Macular EdemaIndonesia
-
Innovent Biologics (Suzhou) Co. Ltd.SuspendedDiabetic Macular Edema | Neovascular Age-related Macular DegenerationChina
-
Chengdu Kanghong Biotech Co., Ltd.TerminatedNeovascular Age-related Macular DegenerationUnited States, Argentina, Australia, Austria, Belgium, Canada, Chile, Colombia, Germany, Hong Kong, Lithuania, Mexico, Netherlands, New Zealand, Peru, Philippines, Poland, Portugal, Singapore, Spain, Switzerland, Taiwan
-
Chengdu Kanghong Biotech Co., Ltd.TerminatedNeovascular Age-related Macular DegenerationUnited States, Bulgaria, China, Czechia, Denmark, France, Hungary, Israel, Italy, Latvia, Slovakia, United Kingdom
-
M. Ali Khan, MDUniversity of California, Los Angeles; Southeastern Retina Associates; Eye Associates...RecruitingProliferative Vitreoretinopathy | Retinal Detachment With Multiple Breaks, Unspecified EyeUnited States
-
Kim's Eye HospitalBayerRecruitingRetinal Angiomatous ProliferationKorea, Republic of
-
Instituto de Olhos de GoianiaUnknownChoroidal Retinal NeovascularizationBrazil
-
Innostellar Biotherapeutics Co.,LtdRecruitingNeovascular Age-Related Macular DegenerationChina
-
Regeneron PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationUnited States
-
Regeneron PharmaceuticalsBayerCompleted